Table 1 Participant demographics and clinical characteristics

Age [years, M (Q ₁, Q ₃)]

67.5 (63, 71)

63 (57, 72)

71 (67, 78) †‡

< 0.001

Gender, males/females

20/34

23/34

30/18 †‡

0.015

Education [years, M (Q ₁, Q ₃)]

12 (9, 15)

10 (9, 14)

12 (9, 16)

0.224

BMI (kg/m²)

24.75 ± 2.98

23.48 ± 3.23

29.90 ± 3.27

0.087

Hypertension, n (%)

23 (42.6%)

18 (32.1%)

24 (50.0%)

0.176

Diabetes, n (%)

7 (13.0%)

5 (8.9%)

11 (22.9%)

0.120

Stroke, n (%)

4 (7.4%)

4 (7.1%)

5 (10.4%)

0.803

Aspirin intake, n (%)

10 (18.5%)

7 (12.5%)

8 (16.7%)

0.676

LDL (mmol/L)

2.91 ± 0.99

2.76 ± 0.85

2.49 ± 0.89

0.077

HDL (mmol/L)

1.43 ± 0.34

1.38 ± 0.33

1.32 ± 0.42

0.260

TC (mmol/L)

4.98 ± 0.94

4.70 ± 0.95

4.59 ± 0.91

0.098

TG (mmol/L)

1.71 ± 0.97

1.40 ± 0.84

1.29 ± 1.08

0.088

MMSE [scores, M (Q ₁, Q ₃)]

28 (28, 29)

18 (13, 22) †

21 (14, 24) †

< 0.001

MoCA [scores, M (Q ₁, Q ₃)]

26 (24, 27)

13 (8, 17) †

13 (8, 19) †

< 0.001

CDT [scores, M (Q ₁, Q ₃)]

3 (3, 3)

1 (0, 2) †

1 (1, 2) †

< 0.001

CDR [scores, M (Q ₁, Q ₃)]

0 (0, 0)

1 (1, 2) †

1 (1, 2) †

< 0.001

UPDRS [scores, M (Q ₁, Q ₃)]

N/A

/

68 (40, 109)

/

Visual hallucinations, n (%)

N/A

/

40 (83.3%)

/

Fluctuations, n (%)

N/A

/

20 (41.7%)

/

Parkinsonism, n (%)

N/A

/

48 (96%)

/

RBD, n (%)

N/A

/

31 (64.6%)

/